| 18/06/19 | 08:00:12 | 18 Jun 2019 | | Lynparza approved in the EU for 1st-line | RNS |
| 17/06/19 | 08:00:06 | 17 Jun 2019 | | Calquence significantly prolonged the time patient | RNS |
| 12/06/19 | 17:45:04 | 12 Jun 2019 | | Publication of a Prospectus | RNS |
| 10/06/19 | 18:12:23 | 10 Jun 2019 | | Result of AGM | RNS |
| 06/06/19 | 08:00:07 | 6 Jun 2019 | | Calquence Phase III ELEVATE-TN trial met primary | RNS |
| 05/06/19 | 17:57:34 | 5 Jun 2019 | | UPDATE ON EUSKALTEL BOARD REPRESENTATION | RNS |
| 03/06/19 | 16:00:05 | 3 Jun 2019 | | Block listing Interim Review | RNS |
| 03/06/19 | 16:00:05 | 3 Jun 2019 | | Total Voting Rights | RNS |
| 03/06/19 | 08:00:09 | 3 Jun 2019 | | Lynparza nearly doubled time patients lived with | RNS |
| 10/05/19 | 16:11:58 | 10 May 2019 | | Director/PDMR Shareholding | RNS |
| 10/05/19 | 08:00:05 | 10 May 2019 | | Pooled analyses of the roxadustat global Phase III | RNS |
| 08/05/19 | 15:00:01 | 8 May 2019 | | Director/PDMR Shareholding | RNS |
| 08/05/19 | 12:00:02 | 8 May 2019 | | Director Declaration | RNS |
| 03/05/19 | 08:00:03 | 3 May 2019 | | Qternmet XR approved in the US for type-2 diabetes | RNS |
| 01/05/19 | 16:00:02 | 1 May 2019 | | Total Voting Rights | RNS |
| 01/05/19 | 13:00:01 | 1 May 2019 | | Director/PDMR Shareholding | RNS |
| 29/04/19 | 08:00:18 | 29 Apr 2019 | | Lynparza receives positive EU CHMP opinion for 1st | RNS |
| 26/04/19 | 18:45:23 | 26 Apr 2019 | | Result of AGM | RNS |
| 26/04/19 | 08:00:08 | 26 Apr 2019 | | AZN: Q1 2019 Results | RNS |
| 25/04/19 | 08:01:01 | 25 Apr 2019 | | Notice of AGM | RNS |
| 25/04/19 | 08:00:07 | 25 Apr 2019 | | Final Results | RNS |
| 04/04/19 | 14:30:01 | 4 Apr 2019 | | Holding(s) in Company | RNS |
| 03/04/19 | 11:00:02 | 3 Apr 2019 | | Director/PDMR Shareholding | RNS |
| 02/04/19 | 16:00:02 | 2 Apr 2019 | | Total Voting Rights | RNS |
| 01/04/19 | 19:00:01 | 1 Apr 2019 | | Astrazeneca | RNS |
| 01/04/19 | 16:00:02 | 1 Apr 2019 | | Total Voting Rights | RNS |
| 01/04/19 | 08:00:06 | 1 Apr 2019 | | Selumetinib gets Breakthrough Therapy Designation | RNS |
| 29/03/19 | 17:15:04 | 29 Mar 2019 | | Results of Placing | RNS |
| 29/03/19 | 07:00:07 | 29 Mar 2019 | | Proposed placing of new ordinary shares | RNS |
| 29/03/19 | 07:00:07 | 29 Mar 2019 | | AZ and Daiichi Sankyo enter collaboration in novel | RNS |
| 27/03/19 | 07:00:05 | 27 Mar 2019 | | Forxiga approved in Japan for type-1 diabetes | RNS |
| 18/03/19 | 07:00:05 | 18 Mar 2019 | | US FDA grants saracatinib ODD for IPF | RNS |
| 14/03/19 | 12:00:02 | 14 Mar 2019 | | Notice of AGM | RNS |
| 12/03/19 | 12:00:01 | 12 Mar 2019 | | Director/PDMR Shareholding | RNS |
| 06/03/19 | 07:00:04 | 6 Mar 2019 | | Filing of Form 20-F with SEC | RNS |
| 05/03/19 | 11:00:02 | 5 Mar 2019 | | Annual Financial Report | RNS |
| 04/03/19 | 16:04:36 | 4 Mar 2019 | | Holding(s) in Company | RNS |
| 01/03/19 | 15:00:01 | 1 Mar 2019 | | Total Voting Rights | RNS |
| 01/03/19 | 13:45:01 | 1 Mar 2019 | | Lynparza receives positive EU CHMP opinion | RNS |
| 26/02/19 | 07:00:26 | 26 Feb 2019 | | Lynparza significantly delayed disease progression | RNS |
| 25/02/19 | 07:00:07 | 25 Feb 2019 | | Brilinta's PhIII THEMIS trial met primary endpoint | RNS |
| 14/02/19 | 07:00:03 | 14 Feb 2019 | | AstraZeneca Full-Year and Q4 2018 Results | RNS |
| 06/02/19 | 07:00:02 | 6 Feb 2019 | | US FDA grants Fasenra Orphan Drug Designation | RNS |
| 05/02/19 | 07:05:01 | 5 Feb 2019 | | US FDA grants Breakthrough Therapy Designation | RNS |
| 05/02/19 | 07:00:07 | 5 Feb 2019 | | EMA grants PRIME eligibility for MEDI8897 | RNS |
| 01/02/19 | 15:00:01 | 1 Feb 2019 | | Total Voting Rights | RNS |
| 01/02/19 | 13:17:55 | 1 Feb 2019 | | Forxiga receives positive EU CHMP opinion | RNS |
| 25/01/19 | 14:00:02 | 25 Jan 2019 | | Completion of divestment of US Synagis rights | RNS |
| 07/01/19 | 13:00:00 | 7 Jan 2019 | | AstraZeneca announces organisational changes | RNS |
| 02/01/19 | 15:00:02 | 2 Jan 2019 | | Total Voting Rights | RNS |
